Recently, Deloitte held the 2025 event in Hong Kong, ChinaTop 40 High-Tech and High-Growth Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area(Hereinafter referred to as: Deloitte Greater Bay Area Top 40) Award Ceremony and List Release Event, Xbiome Co. Ltd. (Hereinafter referred to as: Xbiome) successfully entered the list with its performance growth and innovation strength in the fields of microbiome pharmaceuticals and healthcare.
Deloitte's "High Tech High Growth" program was founded in the United States in 1995 and is held annually in dozens of countries and regions around the world, being hailed as"Benchmark of High-Growth Enterprises" "Cradle of Great Technology Companies"Deloitte Greater Bay Area Top 40 uses the cumulative revenue growth rate of enterprises as the core evaluation index, while strictly examining indicators such as independent intellectual property rights, technological innovation capabilities, business model sustainability, and industry development prospects.Is one of the most authoritative science and technology innovation trend indicators in the Guangdong-Hong Kong-Macao Greater Bay Area.
This year's selection, themed "Innovation Without Boundaries, Resilient Growth," aligns closely with Xbiome's core development and growth trajectory. Xbiome focuses on the human intestinal microbiome, leveraging its technology platform and scientific research to drive technological innovation and industrialization in areas including drug research, Fecal Microbiota Transplantation (FMT), and probiotics. The company is set to enter a significant commercialization phase in 2025 to 2026.
The company is developing a completely new FMT product matrix to cater to people of different ages and health needs.Standard Edition FMT, Precision Edition FMT, Super Edition FMTThree products precisely reconstruct the user's microbiome, repairing the human body's sub-health state from the intestinal origin and fulfilling health needs. Meanwhile, Xbiome has devoted its efforts to developing...Heavyweight Products in the Anti-Aging Series, has also entered the countdown stage for its market launch, providing consumers with a scientifically evidenced, safe, and effective new choice for anti-aging.
With its remarkable achievements in FMT and probiotics, Xbiome has achieved steady growth in its core business. Amid an uncertain external environment, the company has demonstrated significant resilience against market cycles, continuously garnering favor and support from investors both domestically and internationally. Its inclusion in Deloitte's Greater Bay Area Top 40 not only represents recognition by authoritative institutions like Deloitte of Xbiome's developmental accomplishments but also affirms the company's future innovation potential.
Xbiome will leverage its deep scientific research foundation and technical barriers to continuously increase R&D investment, accelerate product commercialization, and create greater health value for global users with higher-quality products and services.
-End-